MDLN · Medline Inc.
AI read · Good for MDLN
The AI's read
This is a favorable outside view of Medline, not a report of stronger sales or profit. The story gives no new company results, so the support comes from the analyst's opinion alone.
A JPMorgan analyst says to buy Medline Inc. and has increased the price target to $47 from $46.
Good for MDLN
JPMorgan kept its Buy rating and raised its target, signaling a more favorable view of Medline. The story reports no new company results, so the support rests on one analyst's opinion.
Get alerts for MDLN
Follow Medline Inc. (MDLN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MDLNFree on the App Store and Google Play, or on the web.